+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation

Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation

Journal of the Chinese Medical Association 73(5): 262-264

Targeted therapy in the management of metastatic renal cell cancer has been recently introduced to urology practice. The drugs used for management are used in a very limited number of patients and only for clear cell histology. We present a case where we administered sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, to a patient with metastatic renal cell carcinoma of clear cell histology. We found that our results were different from those of previously reported studies, because sarcomatoid differentiation was evident in a histological examination of this case. There was an excellent response to sorafenib. This case report might provide evidence that antiangiogenic agents may be active in any histological type of renal cell carcinoma. However, there are no available data to demonstrate the duration of response and survival benefit.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 055854261

Download citation: RISBibTeXText

PMID: 20685594

DOI: 10.1016/s1726-4901(10)70056-3

Related references

c-KIT: potential predictive factor for the efficacy of sorafenib in metastatic renal cell carcinoma with sarcomatoid feature. Clinical Genitourinary Cancer 11(2): 134-140, 2014

Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma. Journal of Surgical Oncology 95(4): 317-323, 2006

Spontaneous regression of metastatic pulmonary renal cell carcinoma in the setting of sarcomatoid differentiation of the primary tumour. Canadian Urological Association Journal 7(9-10): E587-E589, 2013

Presence of sarcomatoid differentiation as a prognostic indicator for survival in surgically treated metastatic renal cell carcinoma. Journal of Cancer Research and Clinical Oncology 143(3): 499-508, 2016

Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. Clinical Genitourinary Cancer 2019, 2019

Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Clinical Genitourinary Cancer 13(2): E79-E85, 2015

Ki-67 index and percentage of sarcomatoid differentiation were two independent prognostic predictors in sarcomatoid renal cell carcinoma. Cancer Management and Research 10: 5339-5347, 2018

Long stabilization of sarcomatoid renal cell carcinoma treated with sorafenib. Actas Urologicas Espanolas 36(6): 385-386, 2012

Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. Annals of Oncology 24(12): 2967-2971, 2014

Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents. Critical Reviews in Oncology/Hematology 99: 324-331, 2016

Combination of gemcitabine and doxorubicin in rapidly progressive metastatic renal cell carcinoma and/or sarcomatoid renal cell carcinoma. Oncology 80(3-4): 214-218, 2011

Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation. European Journal of Medical Research 15: 287-291, 2012

Efficacy and safety of long-term use of sorafenib: final report of a phase Ii trial of sorafenib in Japanese patients with unresectable/metastatic renal cell carcinoma. European Journal of Cancer Suppl.s 7(2): 437-438, 2009

Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma. Bju International 108(11): 1813-1819, 2011

Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. Journal of Clinical Oncology 26(15_Suppl): 5127-5127, 2016